Allogene Therapeutics (ALLO) Ownership - Who Owns Allogene Therapeutics?

1,758 Followers

Allogene Therapeutics (ALLO) Ownership Overview

6.95% Insiders

8.28% Mutual Funds

2.28% Other Institutional Investors

8.05% ETFs

74.43% Public Companies and

Individual Investors

The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 18.62% of the company’s stock is owned by Institutional Investors, 6.95% is owned by Insiders, and 74.43% is owned by Public Companies and Individual Investors.

The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 10.57% of the company’s stock is owned by Institutional Investors, 6.95% is owned by Insiders, and 8.05% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date	Name	Activity	Value

Show More Insider Trading Activity >

Recent Hedge Fund Trading Activity

Date	Firm	Activity	Value
Dec 31, 2023	Primecap Management Co	xxxxxxxxxxxxx	$11151581
Dec 31, 2023	Graham Capital Management, L.p.	xxxxxxxxxxxxx	$203679
Dec 31, 2023	Woodline Partners Lp	xxxxxxxxxxxxx	$4795684

Show More Hedge Fund Trading Activity >

Top Shareholders

Holder	# of Shares	Type	% Holding	Value
	11,009,103	Insider	3.32%	23,669,571
	8,456,397	Institution	2.55%	18,181,254
Theofanis Kolokotrones	8,139,840	Institution	2.46%	17,500,656
	8,063,795	Insider	2.43%	17,337,159
	7,432,042	Institution	2.24%	15,978,890
	6,678,789	Institution	2.02%	14,359,396
	6,198,294	Institution	1.87%	13,326,332
	5,189,570	Institution	1.57%	11,157,576
Michael Rockefeller	3,500,499	Institution	1.06%	7,526,073
Len Potter	2,920,787	Institution	0.88%	6,279,692

Top Mutual Fund Holders

# of Shares	Type	% Holding	Value
6,678,789	Institution	2.02%	14,359,396
5,189,570	Institution	1.57%	11,157,576
2,745,270	Institution	0.83%	5,902,331
2,147,980	Institution	0.65%	4,618,157
1,733,105	Institution	0.52%	3,726,176
1,709,989	Institution	0.52%	3,676,476
1,401,115	Institution	0.42%	3,012,397
1,208,862	Institution	0.36%	2,599,053
885,754	Institution	0.27%	1,904,371
600,290	Institution	0.18%	1,290,624

Top ETF Holders

Holder	# of Shares	Type	% Holding	Value
SPDR S&P BIOTECH ETF	5,928,839	Institution	1.79%	12,628,427
Vanguard Total Stock Market ETF	4,879,191	Institution	1.47%	11,905,226
iShares Russell 2000 ETF	3,684,904	Institution	1.11%	7,922,544
Vanguard Extended Market ETF	1,883,094	Institution	0.57%	4,594,749
iShares Biotechnology ETF	1,694,031	Institution	0.51%	3,642,167
iShares Russell 2000 Value ETF	1,343,181	Institution	0.41%	2,887,839
Schwab U.S. Small-Cap ETF	1,229,757	Institution	0.37%	2,619,382
Dimensional U.S. Small Cap ETF	876,401	Institution	0.26%	1,866,734
Vanguard Russell 2000 ETF	769,244	Institution	0.23%	1,876,955
Fidelity Enhanced Small Cap ETF	576,739	Institution	0.17%	1,228,454

FAQ

Who Owns Allogene Therapeutics Inc (ALLO)?

According to the latest TipRanks data, approximately 2.28% of the company's stock is held by institutional investors, 6.95% is held by insiders, and 74.43% is held by retail investors.

What percentage of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors?

According to the latest TipRanks data, approximately 2.28% of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors.

What percentage of Allogene Therapeutics Inc (ALLO) stock is held by retail investors?

According to the latest TipRanks data, approximately 74.43% of Allogene Therapeutics Inc (ALLO) stock is held by retail investors.

Who owns the most shares of Allogene Therapeutics Inc (ALLO)?

Arie Belldegrun owns the most shares of Allogene Therapeutics Inc (ALLO).

What is the significance of the ownership structure for a publicly traded company?

The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.